Ology Bioservices Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- GDPH3533938D
- Pages: 25
- September 2018
- Total Views:1131
- Region : North America
- GlobalData
- Equity Research Report

Details
Summary
Ology Bioservices Inc (Ology Bioservices), formerly Nanotherapeutics, Inc., is an integrated biopharmaceutical company which provides contract development and manufacturing services. The company manufactures biopharmaceutical products such as vaccines, antibodies, protein therapies and medical devices. Its CDMO services include process development, quality control testing, cGMP manufacturing of bulk drug substances, cell line development, scale-up, and production, bioanalytical services, project management, among others. Ology Bioservices also provide vaccine programs available for partnering and/or licensing to treat ross river (Phase III), chikungunya, pandemic, seasonal flu vaccines, yellow fever (MVA), typhoid, west nile and norovirus. The company has operations in Maryland, California, and London. Ology Bioservices is headquartered in Alachua, Florida, the US.
Ology Bioservices Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table Of Content
Scope
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Ology Bioservices Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Ology Bioservices Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Ology Bioservices Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Ology Bioservices Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Ology Bioservices Inc, Medical Devices Deals, 2012 to YTD 2018 9
Ology Bioservices Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Ology Bioservices Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Nanotherapeutics Ammends agreement with XOMA 11
Nanotherapeutics Acquires Vero Cell Technology from Baxter 13
Venture Financing 14
Nanotherapeutics Secures USD28.5 Million in Venture Debt Financing 14
Partnerships 15
Takeda Pharma Enters into Agreement with Nanotherapeutics 15
Licensing Agreements 16
Trethera Enters into Licensing Agreement with Nanotherapeutics 16
Acquisition 17
Serum Institute of India Acquires Nanotherapeutics for USD78.2 Million 17
Ology Bioservices Inc-Key Competitors 18
Ology Bioservices Inc-Key Employees 19
Ology Bioservices Inc-Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Recent Developments 21
Strategy And Business Planning 21
May 02, 2017: Nanotherapeutics Bohumil and Praha Vaccines Finalize Transfer of Human Vaccine Manufacturing Enterprise in the Czech Republic 21
Corporate Communications 22
Apr 03, 2018: Ology Bioservices Strengthens Board of Directors with Appointment of Industry Veterans James M. Robinson and Gerard Cunningham 22
Jun 22, 2017: Robert J. Hennessey Appointed Chairman of the Board of Nanotherapeutics 23
Jun 20, 2017: Peter H. Khoury, Ph.D., MBA Appointed President and Chief Executive Officer of Nanotherapeutics 24
Appendix 25
Methodology 25
About GlobalData 25
Contact Us 25
Disclaimer 25
List Of Figure
List of Figures
Ology Bioservices Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Ology Bioservices Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Ology Bioservices Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Ology Bioservices Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Ology Bioservices Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Ology Bioservices Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Ology Bioservices Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Ology Bioservices Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Ology Bioservices Inc, Medical Devices Deals, 2012 to YTD 2018 9
List Of Table
List of Tables
Ology Bioservices Inc, Pharmaceuticals & Healthcare, Key Facts 2
Ology Bioservices Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Ology Bioservices Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Ology Bioservices Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Ology Bioservices Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Ology Bioservices Inc, Medical Devices Deals, 2012 to YTD 2018 9
Ology Bioservices Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Nanotherapeutics Ammends agreement with XOMA 11
Nanotherapeutics Acquires Vero Cell Technology from Baxter 13
Nanotherapeutics Secures USD28.5 Million in Venture Debt Financing 14
Takeda Pharma Enters into Agreement with Nanotherapeutics 15
Trethera Enters into Licensing Agreement with Nanotherapeutics 16
Serum Institute of India Acquires Nanotherapeutics for USD78.2 Million 17
Ology Bioservices Inc, Key Competitors 18
Ology Bioservices Inc, Key Employees 19
Ology Bioservices Inc, Other Locations 20
Ology Bioservices Inc, Subsidiaries 20
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products and Companies
Products
Ology Bioservices Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Company Profile
Company Profile Title
Summary
Ology Bioservices Inc (Ology Bioservices), formerly Nanotherapeutics, Inc., is an integrated biopharmaceutical company which provides contract development and manufacturing services. The company manufactures biopharmaceutical products such as vaccines, antibodies, protein therapies and medical devices. Its CDMO services include process development, quality control testing, cGMP manufacturing of bulk drug substances, cell line development, scale-up, and production, bioanalytical services, project management, among others. Ology Bioservices also provide vaccine programs available for partnering and/or licensing to treat ross river (Phase III), chikungunya, pandemic, seasonal flu vaccines, yellow fever (MVA), typhoid, west nile and norovirus. The company has operations in Maryland, California, and London. Ology Bioservices is headquartered in Alachua, Florida, the US.
Ology Bioservices Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Scope
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Ology Bioservices Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Ology Bioservices Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Ology Bioservices Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Ology Bioservices Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Ology Bioservices Inc, Medical Devices Deals, 2012 to YTD 2018 9
Ology Bioservices Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Ology Bioservices Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Nanotherapeutics Ammends agreement with XOMA 11
Nanotherapeutics Acquires Vero Cell Technology from Baxter 13
Venture Financing 14
Nanotherapeutics Secures USD28.5 Million in Venture Debt Financing 14
Partnerships 15
Takeda Pharma Enters into Agreement with Nanotherapeutics 15
Licensing Agreements 16
Trethera Enters into Licensing Agreement with Nanotherapeutics 16
Acquisition 17
Serum Institute of India Acquires Nanotherapeutics for USD78.2 Million 17
Ology Bioservices Inc-Key Competitors 18
Ology Bioservices Inc-Key Employees 19
Ology Bioservices Inc-Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Recent Developments 21
Strategy And Business Planning 21
May 02, 2017: Nanotherapeutics Bohumil and Praha Vaccines Finalize Transfer of Human Vaccine Manufacturing Enterprise in the Czech Republic 21
Corporate Communications 22
Apr 03, 2018: Ology Bioservices Strengthens Board of Directors with Appointment of Industry Veterans James M. Robinson and Gerard Cunningham 22
Jun 22, 2017: Robert J. Hennessey Appointed Chairman of the Board of Nanotherapeutics 23
Jun 20, 2017: Peter H. Khoury, Ph.D., MBA Appointed President and Chief Executive Officer of Nanotherapeutics 24
Appendix 25
Methodology 25
About GlobalData 25
Contact Us 25
Disclaimer 25
List Of Figure
List of Figures
Ology Bioservices Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Ology Bioservices Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Ology Bioservices Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Ology Bioservices Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Ology Bioservices Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Ology Bioservices Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Ology Bioservices Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Ology Bioservices Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Ology Bioservices Inc, Medical Devices Deals, 2012 to YTD 2018 9
List Of Table
List of Tables
Ology Bioservices Inc, Pharmaceuticals & Healthcare, Key Facts 2
Ology Bioservices Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Ology Bioservices Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Ology Bioservices Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Ology Bioservices Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Ology Bioservices Inc, Medical Devices Deals, 2012 to YTD 2018 9
Ology Bioservices Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Nanotherapeutics Ammends agreement with XOMA 11
Nanotherapeutics Acquires Vero Cell Technology from Baxter 13
Nanotherapeutics Secures USD28.5 Million in Venture Debt Financing 14
Takeda Pharma Enters into Agreement with Nanotherapeutics 15
Trethera Enters into Licensing Agreement with Nanotherapeutics 16
Serum Institute of India Acquires Nanotherapeutics for USD78.2 Million 17
Ology Bioservices Inc, Key Competitors 18
Ology Bioservices Inc, Key Employees 19
Ology Bioservices Inc, Other Locations 20
Ology Bioservices Inc, Subsidiaries 20
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products
Ology Bioservices Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.